AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AIDS Therapies
Potent New Nucleoside Analog May Replace Lamivudine
August 23rd, 1999
A potent new drug may ultimately replace one of the mainstays of AIDS therapy. The new drug is the racemic nucleoside-analog reverse transcriptase inhibitor (NARTI) 2'-deoxy-3'-oxa-4'-thiocytidine (dOTC). It is structurally related to lamivudine (trade name, Epivir, Glaxo): (-) enantiomeric 2'-deoxy-3'-thiocytidine. Because it greatly enhances the potency of other NARTIs, lamivudine is one of the most frequently used antiretroviral agents. New studies by researchers associated with BioChem Pharma show that the company's dOTC is more potent than 3TC and, at least in vitro, far slower to give rise to resistance mutations. It also retains its...
Source: AIDS Weekly (1999-08-23)
|
